
Ipatasertib Plus Fulvestrant Demonstrates Significant PFS Benefit in ER+/HER2– Metastatic Breast Cancer
Ipatasertib in combination with fulvestrant (Faslodex) significantly prolonged progression-free survival (PFS) compared with placebo plus fulvestrant in patients with estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer following disease …